Neurocognitive and behavioural performance of healthy volunteers receiving an increasing analgesic-range infusion of ketamine

Amie Hayley, Maja Green, Luke Downey, Michael Keane, Panagiota Kostakis, Yahya Shehabi

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

Background: The acute and delayed effect of analgesic-range doses of ketamine on neurocognitive and behavioural outcomes is understudied. Using a non-controlled open-labelled design, three (1-h duration) increasing intravenous (IV) ketamine infusions comprising (i) 30 mg bolus of ketamine + 8 mg/h IV infusion, (ii) 12 mg/h IV infusion and (iii) 20 mg/h infusion were administered to 20 participants (15 male, 5 female, mean age = 30.8 years). Whole-blood ketamine and norketamine concentrations were determined at each treatment step and post-infusion. Methods: The Cambridge Neuropsychological Test Automated Battery (CANTAB) was used to assess reaction/movement time (RTI, Simple and 5-Choice), visuospatial working memory (SWM), spatial planning (SOC) and subjective effects (visual analogue scale; VAS) during treatment and at post-treatment. Results: Significant main effects were reported for time (dose) on CANTAB RTI 5-Choice reaction (F(4,18) = 3.41, p = 0.029) and movement time (F(4,18) = 4.42, p = 0.011), SWM (F(4,18) = 4.19, p = 0.014) and SOC (F(4,18) = 4.13, p = 0.015), but not RTI Simple reaction or movement time. Post hoc analyses revealed dose-dependent effects for both RTI 5-Choice reaction and movement time (all p < 0.05). Post-treatment performance on all neurocognitive and behavioural tasks returned to baseline levels. Regression analyses revealed a weak positive linear association between SWM ‘strategy’ score (R2 = 0.103, p < 0.001), all performance-based CANTAB VAS items (R2 range 0.005–0.137, all p < 0.05) and ketamine blood concentrations. Discussion: The open-label, non-controlled trial design somewhat precludes the ability to adequately account for random treatment effects. Notwithstanding, these results suggest that analgesic doses of ketamine produce acute, selective, dose-dependent deficits in higher-order neurocognitive and behavioural domains.

Original languageEnglish
Pages (from-to)1273-1282
Number of pages10
JournalPsychopharmacology
Volume235
Issue number4
DOIs
Publication statusPublished - 1 Apr 2018

Keywords

  • Behavioural
  • Intravenous
  • Ketamine
  • Neurocognitive
  • Therapeutic

Cite this

@article{e5ec2aa4020041a0b18c5c2417ef0494,
title = "Neurocognitive and behavioural performance of healthy volunteers receiving an increasing analgesic-range infusion of ketamine",
abstract = "Background: The acute and delayed effect of analgesic-range doses of ketamine on neurocognitive and behavioural outcomes is understudied. Using a non-controlled open-labelled design, three (1-h duration) increasing intravenous (IV) ketamine infusions comprising (i) 30 mg bolus of ketamine + 8 mg/h IV infusion, (ii) 12 mg/h IV infusion and (iii) 20 mg/h infusion were administered to 20 participants (15 male, 5 female, mean age = 30.8 years). Whole-blood ketamine and norketamine concentrations were determined at each treatment step and post-infusion. Methods: The Cambridge Neuropsychological Test Automated Battery (CANTAB) was used to assess reaction/movement time (RTI, Simple and 5-Choice), visuospatial working memory (SWM), spatial planning (SOC) and subjective effects (visual analogue scale; VAS) during treatment and at post-treatment. Results: Significant main effects were reported for time (dose) on CANTAB RTI 5-Choice reaction (F(4,18) = 3.41, p = 0.029) and movement time (F(4,18) = 4.42, p = 0.011), SWM (F(4,18) = 4.19, p = 0.014) and SOC (F(4,18) = 4.13, p = 0.015), but not RTI Simple reaction or movement time. Post hoc analyses revealed dose-dependent effects for both RTI 5-Choice reaction and movement time (all p < 0.05). Post-treatment performance on all neurocognitive and behavioural tasks returned to baseline levels. Regression analyses revealed a weak positive linear association between SWM ‘strategy’ score (R2 = 0.103, p < 0.001), all performance-based CANTAB VAS items (R2 range 0.005–0.137, all p < 0.05) and ketamine blood concentrations. Discussion: The open-label, non-controlled trial design somewhat precludes the ability to adequately account for random treatment effects. Notwithstanding, these results suggest that analgesic doses of ketamine produce acute, selective, dose-dependent deficits in higher-order neurocognitive and behavioural domains.",
keywords = "Behavioural, Intravenous, Ketamine, Neurocognitive, Therapeutic",
author = "Amie Hayley and Maja Green and Luke Downey and Michael Keane and Panagiota Kostakis and Yahya Shehabi",
year = "2018",
month = "4",
day = "1",
doi = "10.1007/s00213-018-4842-7",
language = "English",
volume = "235",
pages = "1273--1282",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer-Verlag London Ltd.",
number = "4",

}

Neurocognitive and behavioural performance of healthy volunteers receiving an increasing analgesic-range infusion of ketamine. / Hayley, Amie; Green, Maja; Downey, Luke; Keane, Michael; Kostakis, Panagiota; Shehabi, Yahya.

In: Psychopharmacology, Vol. 235, No. 4, 01.04.2018, p. 1273-1282.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Neurocognitive and behavioural performance of healthy volunteers receiving an increasing analgesic-range infusion of ketamine

AU - Hayley, Amie

AU - Green, Maja

AU - Downey, Luke

AU - Keane, Michael

AU - Kostakis, Panagiota

AU - Shehabi, Yahya

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: The acute and delayed effect of analgesic-range doses of ketamine on neurocognitive and behavioural outcomes is understudied. Using a non-controlled open-labelled design, three (1-h duration) increasing intravenous (IV) ketamine infusions comprising (i) 30 mg bolus of ketamine + 8 mg/h IV infusion, (ii) 12 mg/h IV infusion and (iii) 20 mg/h infusion were administered to 20 participants (15 male, 5 female, mean age = 30.8 years). Whole-blood ketamine and norketamine concentrations were determined at each treatment step and post-infusion. Methods: The Cambridge Neuropsychological Test Automated Battery (CANTAB) was used to assess reaction/movement time (RTI, Simple and 5-Choice), visuospatial working memory (SWM), spatial planning (SOC) and subjective effects (visual analogue scale; VAS) during treatment and at post-treatment. Results: Significant main effects were reported for time (dose) on CANTAB RTI 5-Choice reaction (F(4,18) = 3.41, p = 0.029) and movement time (F(4,18) = 4.42, p = 0.011), SWM (F(4,18) = 4.19, p = 0.014) and SOC (F(4,18) = 4.13, p = 0.015), but not RTI Simple reaction or movement time. Post hoc analyses revealed dose-dependent effects for both RTI 5-Choice reaction and movement time (all p < 0.05). Post-treatment performance on all neurocognitive and behavioural tasks returned to baseline levels. Regression analyses revealed a weak positive linear association between SWM ‘strategy’ score (R2 = 0.103, p < 0.001), all performance-based CANTAB VAS items (R2 range 0.005–0.137, all p < 0.05) and ketamine blood concentrations. Discussion: The open-label, non-controlled trial design somewhat precludes the ability to adequately account for random treatment effects. Notwithstanding, these results suggest that analgesic doses of ketamine produce acute, selective, dose-dependent deficits in higher-order neurocognitive and behavioural domains.

AB - Background: The acute and delayed effect of analgesic-range doses of ketamine on neurocognitive and behavioural outcomes is understudied. Using a non-controlled open-labelled design, three (1-h duration) increasing intravenous (IV) ketamine infusions comprising (i) 30 mg bolus of ketamine + 8 mg/h IV infusion, (ii) 12 mg/h IV infusion and (iii) 20 mg/h infusion were administered to 20 participants (15 male, 5 female, mean age = 30.8 years). Whole-blood ketamine and norketamine concentrations were determined at each treatment step and post-infusion. Methods: The Cambridge Neuropsychological Test Automated Battery (CANTAB) was used to assess reaction/movement time (RTI, Simple and 5-Choice), visuospatial working memory (SWM), spatial planning (SOC) and subjective effects (visual analogue scale; VAS) during treatment and at post-treatment. Results: Significant main effects were reported for time (dose) on CANTAB RTI 5-Choice reaction (F(4,18) = 3.41, p = 0.029) and movement time (F(4,18) = 4.42, p = 0.011), SWM (F(4,18) = 4.19, p = 0.014) and SOC (F(4,18) = 4.13, p = 0.015), but not RTI Simple reaction or movement time. Post hoc analyses revealed dose-dependent effects for both RTI 5-Choice reaction and movement time (all p < 0.05). Post-treatment performance on all neurocognitive and behavioural tasks returned to baseline levels. Regression analyses revealed a weak positive linear association between SWM ‘strategy’ score (R2 = 0.103, p < 0.001), all performance-based CANTAB VAS items (R2 range 0.005–0.137, all p < 0.05) and ketamine blood concentrations. Discussion: The open-label, non-controlled trial design somewhat precludes the ability to adequately account for random treatment effects. Notwithstanding, these results suggest that analgesic doses of ketamine produce acute, selective, dose-dependent deficits in higher-order neurocognitive and behavioural domains.

KW - Behavioural

KW - Intravenous

KW - Ketamine

KW - Neurocognitive

KW - Therapeutic

UR - http://www.scopus.com/inward/record.url?scp=85044504026&partnerID=8YFLogxK

U2 - 10.1007/s00213-018-4842-7

DO - 10.1007/s00213-018-4842-7

M3 - Article

VL - 235

SP - 1273

EP - 1282

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -